| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 17th December 2020 | Edward Wholihan | 68,550 | Open or private sale | $1.36 | $93,228.00 |
| 17th December 2020 | Edward Wholihan | 164,822 | Exercise of derivative | $0.00 | |
| 17th December 2020 | Louis Md Brenner | 103,116 | Open or private sale | $1.36 | $140,237.76 |
| 17th December 2020 | Louis Md Brenner | 247,932 | Exercise of derivative | $0.00 |
Allena Pharmaceuticals
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Allena Pharmaceuticals, Inc. engages in the development, discovery, and commercialization of oral enzyme therapeutics to treat patients with kidney disorders. Its product pipeline includes Reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria in adults. The company was founded by Robert Gallotto and Alexey L. Margolin on June 24, 2011.
Ticker: ALNA
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1624658
Employees:
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
Restructuring Charges of $600 Th for the period Nov 2019 to Nov 2019 in the context of all up
Fundamentals
News
Allena Pharmaceuticals Announces $10.0 Million Bought Deal Offering
1st December 2020